Fundamenta TherapeuticsLtd.
Chimeric Antigen Receptor T-cells(Fundamenta Therapeutics, Ltd.)은 Platinum-Resistant Ovarian Carcinoma 표적 세포·유전자 치료로, Leukemia, Acute Lymphocytic (ALL); Leukemia, Acute Myelogenous (AML) 영역에서 개발·상용화 중입니다. 작용기전: CAR-T and BsAb therapy, as an independent and alternative niche. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 67% (ClinicalTrials.gov NCT03704298). 차별점: unique and independent role, expanding the CAR-T and BsAb-dominated paradigm to address unmet clinical needs.
Platinum-Resistant Ovarian Carcinoma
Leukemia, Acute Lymphocytic (ALL); Leukemia, Acute Myelogenous (AML)
Active
bispecific antibody duopoly: ex vivo armed T cells for solid tumors
lentiviral expression vector and removed epitope tags used to discriminate between CAR and
humanized scFvs, hinge/TM optimization, and ITAM calibration have been developed, along with programmable "sw
unique and independent role, expanding the CAR-T and BsAb-dominated paradigm to address unmet clinical needs
CAR-T and BsAb therapy, as an independent and alternative niche
cytokine release syndrome
Biomarker potential and therapeutic targeting to counteract drug resistance
escape via heterogeneity and target antigen loss, and treatment-related toxicities like cytokine release syndrome
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Fundamenta TherapeuticsLtd.
Chimeric Antigen Receptor T-cells(Fundamenta Therapeutics, Ltd.)은 Platinum-Resistant Ovarian Carcinoma 표적 세포·유전자 치료로, Leukemia, Acute Lymphocytic (ALL); Leukemia, Acute Myelogenous (AML) 영역에서 개발·상용화 중입니다. 작용기전: CAR-T and BsAb therapy, as an independent and alternative niche. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 67% (ClinicalTrials.gov NCT03704298). 차별점: unique and independent role, expanding the CAR-T and BsAb-dominated paradigm to address unmet clinical needs.
Platinum-Resistant Ovarian Carcinoma
Leukemia, Acute Lymphocytic (ALL); Leukemia, Acute Myelogenous (AML)
Active
bispecific antibody duopoly: ex vivo armed T cells for solid tumors
lentiviral expression vector and removed epitope tags used to discriminate between CAR and
humanized scFvs, hinge/TM optimization, and ITAM calibration have been developed, along with programmable "sw
unique and independent role, expanding the CAR-T and BsAb-dominated paradigm to address unmet clinical needs
CAR-T and BsAb therapy, as an independent and alternative niche
cytokine release syndrome
Biomarker potential and therapeutic targeting to counteract drug resistance
escape via heterogeneity and target antigen loss, and treatment-related toxicities like cytokine release syndrome
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.